PMID- 27152880
OWN - NLM
STAT- MEDLINE
DCOM- 20171121
LR  - 20180226
IS  - 2047-2927 (Electronic)
IS  - 2047-2919 (Linking)
VI  - 4
IP  - 5
DP  - 2016 Sep
TI  - Tamoxifen in men: a review of adverse events.
PG  - 776-88
LID - 10.1111/andr.12197 [doi]
AB  - Tamoxifen is an off-label option to treat men for breast cancer, infertility, and 
      idiopathic gynecomastia. Lately, tamoxifen has been proposed as a treatment to 
      prevent gynecomastia in prostate cancer patients receiving antiandrogen therapy. 
      We reviewed the adverse events (AEs) reported in studies of men prescribed 
      tamoxifen for these conditions to better understand its side-effect profile. We 
      searched PubMed for randomized controlled trials (RCTs) that included safety data 
      of tamoxifen treatment in men with prostate cancer, breast cancer, infertility, 
      and idiopathic gynecomastia. Non-RCTs were also reviewed. The results demonstrate 
      that the AE profile in tamoxifen-treated male populations varied. Excluding 
      breast events, gastrointestinal, and cardiovascular problems were the most 
      commonly reported AEs in prostate cancer patients, whereas more psychiatric 
      disorders were reported in male breast cancer patients. Few AEs have been 
      documented in men receiving tamoxifen for infertility and idiopathic 
      gynecomastia. Less than 5% of men withdrew from tamoxifen therapy because of 
      toxicity. This suggests that for most men, tamoxifen is well-tolerated. Of those 
      who discontinued tamoxifen, the majority were male breast cancer patients, and 
      cardiovascular events were the most common reason for stopping tamoxifen 
      treatment. Unfortunately, in many cases, the reasons for withdrawing tamoxifen 
      were unspecified. Based on the available evidence, tamoxifen's AE profile appears 
      to vary depending upon which male population is treated. Also, the frequency at 
      which AEs occur varies - less AEs in men with infertility and idiopathic 
      gynecomastia compared to men with prostate cancer or breast cancer. Long-term 
      studies that rigorously document the side-effect profile of tamoxifen in men are 
      lacking.
CI  - (c) 2016 American Society of Andrology and European Academy of Andrology.
FAU - Wibowo, E
AU  - Wibowo E
AD  - Vancouver Prostate Centre, Vancouver Coastal Health Research Institute, 
      Vancouver, BC, Canada.
FAU - Pollock, P A
AU  - Pollock PA
AD  - Vancouver Prostate Centre, Vancouver Coastal Health Research Institute, 
      Vancouver, BC, Canada.
FAU - Hollis, N
AU  - Hollis N
AD  - Solid Organ Transplant Clinic, Vancouver General Hospital, Vancouver, BC, Canada.
FAU - Wassersug, R J
AU  - Wassersug RJ
AD  - Department of Urologic Sciences, University of British Columbia, Vancouver, BC, 
      Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160506
PL  - England
TA  - Andrology
JT  - Andrology
JID - 101585129
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Selective Estrogen Receptor Modulators)
RN  - 094ZI81Y45 (Tamoxifen)
SB  - IM
MH  - Antineoplastic Agents, Hormonal/*adverse effects/therapeutic use
MH  - Breast Neoplasms, Male/*drug therapy
MH  - Gynecomastia/*drug therapy
MH  - Humans
MH  - Infertility, Male/*drug therapy
MH  - Male
MH  - Off-Label Use
MH  - Prostatic Neoplasms/*drug therapy
MH  - Selective Estrogen Receptor Modulators/*adverse effects/therapeutic use
MH  - Tamoxifen/*adverse effects/therapeutic use
OTO - NOTNLM
OT  - adverse events
OT  - antiandrogen
OT  - breast cancer
OT  - gynecomastia
OT  - infertility
OT  - males
OT  - prostate cancer
OT  - tamoxifen
EDAT- 2016/05/07 06:00
MHDA- 2017/11/29 06:00
CRDT- 2016/05/07 06:00
PHST- 2015/09/18 00:00 [received]
PHST- 2016/03/09 00:00 [revised]
PHST- 2016/03/12 00:00 [accepted]
PHST- 2016/05/07 06:00 [entrez]
PHST- 2016/05/07 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 10.1111/andr.12197 [doi]
PST - ppublish
SO  - Andrology. 2016 Sep;4(5):776-88. doi: 10.1111/andr.12197. Epub 2016 May 6.